
Opinion|Videos|September 17, 2024
Innovations and Future Directions in Higher Risk MDS Treatments
Medical experts discuss innovations and future directions in treatments for higher-risk MDS.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the key challenges in developing effective therapies for patients with TP53-mutated higher-risk myelodysplastic syndromes (MDS), and what strategies are being explored to address these challenges?
- What innovations in the pipeline for higher-risk MDS treatments are you most excited about? What role do you think novel targeted therapies and/or combination therapy will have in future MDS treatment paradigms?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention
2
INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD
3
AI Reshaping Diabetes Care From Nutrition to Clinical Decisions
4
Social Factors Shape Diabetes, Dementia Risk Across Populations
5
